Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: Ellen who wrote (1346)	7/28/1999 1:09:00 PM
From: CMon	Read Replies (2) \| Respond to of 1432

<<Do you know that it isn't?>> 1) Yes. But even so: 2) ABT is a $65 billion pharmaceutical giant. Their top line in 1998 was over $12 billion. Just think, for a moment, about the absurdity of the statement that ABT would devote 1/3 of their sales force to selling only Hextend. If I told you about a company that sold one product: a computer mouse, that was no different that any other mouse for that matter, and that IBM, which already sells mice was planning to devote 1/3 of their entire sales force to sell my product, would you not laugh in my face? If you are that gullible, let me help focus your thinking: Take the most optimistic of the absurd sales forecasts made by the bulls and figure out what gross profit that might translate into for ABT under generous assumptions. What percent of their existing gross is that? Would you, as an ABT manager, like to explain to the shareholders why 1/3 of you salesforce has been tasked to generate that percent of your gross? Or to your boss for that matter?